Drugs / Pimivalimab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03790488 | Dec 2018 → Jul 2019 | cancer | Jounce Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04669899 | Jan 2021 → Nov 2023 | cancer | Jounce Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04549025 | Oct 2020 → Apr 2024 | non-small cell lung carcinoma | Jounce Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pimivalimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04669899 ↗ |
| Known as | JTX-4014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03790488 ↗ |
| Action | Inhibit | “JTX-4014 is a fully human IgG4 monoclonal antibody designed to specifically bind to PD-1 and block its interaction with its ligands, PD-L1 and PD-L2, to augment anti-tumor T...” NCT03790488 ↗1“Programmed cell death protein 1 inhibitor” CHEMBL4650482 ↗ |
| Modality | Monoclonal antibody | “JTX-4014 is a fully human IgG4 monoclonal antibody designed to specifically bind to PD-1 and block its interaction with its ligands, PD-L1 and PD-L2, to augment anti-tumor T...” NCT03790488 ↗ |
| Route | Intravenous | “Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion” NCT03790488 ↗ |
| Target | PDCD1 | “Programmed cell death protein 1 inhibitor” CHEMBL4650482 ↗ |